Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: New, wide-spectrum anti-HIV-1 agents active at (Sub)-nanomolar level

Journal of Medicinal Chemistry

Volumn 54, Issue 8, 2011, Pages 3091-3096

  Rotili, Dante ^a   Tarantino, Domenico ^a   Artico, Marino ^a   Nawrozkij, Maxim B ^b   Gonzalez Ortega, Emmanuel ^c   Clotet, Bonaventura ^c   Samuele, Alberta ^d   Esté, José A ^c   Maga, Giovanni ^d   Mai, Antonello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b VOLGOGRAD STATE TECHNICAL UNIVERSITY   (Russian Federation)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIMIDINE DERIVATIVE; 4 CHLOROPYRIMIDINE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZENE DERIVATIVE; DAPIVIRINE; EFAVIRENZ; ETRAVIRINE; MC 1220; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN;

ANTI-HIV AGENTS; HIV-1; PYRIMIDINES;

EID: 79955455754     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101626c     Document Type: Article

References (30)

1. WHO/UNAIDS AIDS Epidemic Update. December 2009.
2. Cihlar, T.; Ray, A. S. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine Antiviral Res. 2010, 85, 39-58
3. Este, J. A.; Cihlar, T. Current status and challenges of antiretroviral research and therapy Antiviral Res. 2010, 85, 25-33
4. de Bethune, M. P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009) Antiviral Res. 2010, 85, 75-90
5. Wensing, A. M.; van Maarseveen, N. M.; Nijhuis, M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance Antiviral Res. 2010, 85, 59-74
6. McColl, D. J.; Chen, X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy Antiviral Res. 2010, 85, 101-118
7. Tilton, J. C.; Doms, R. W. Entry inhibitors in the treatment of HIV-1 infection Antiviral Res. 2010, 85, 91-100
8. Este, J. A.; Telenti, A. HIV entry inhibitors Lancet 2007, 370, 81-88 (Pubitemid 47018315)
9. Broder, S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic Antiviral Res. 2010, 85, 1-18
10. Moreno, S.; López Aldeguer, J.; Arribas, J. R.; Domingo, P.; Iribarren, J. A.; Ribera, E.; Rivero, A.; Pulido, F. The future of antiretroviral therapy: challenges and needs J. Antimicrob. Chemother. 2010, 65, 827-835
11. Johnson, L. B.; Saravolatz, L. D. Etravirine, a next generation non-nucleoside reverse-transcriptase inhibitor Clin. Infect. Dis. 2009, 48, 1123-1128
12. Artico, M. Selected non-nucleoside reverse transcriptase inhibitors (NNRTIs): the DABOs family Drugs Future 2002, 27, 159-175 and references therein cited. (Pubitemid 34475137)
13. Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Novellino, E.; Greco, G.; Loi, A. G.; Tramontano, E.; Marongiu, M. E.; La Colla, P. 5-Alkyl-2-(alkylthio)- 6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3 H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives J. Med. Chem. 1999, 42, 619-627 (Pubitemid 29110778)
14. Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Novellino, E.; Greco, G.; Lavecchia, A.; Musiu, C.; La Colla, M.; Murgioni, C.; La Colla, P.; Loddo, R. Structure-Based Design, Synthesis, and Biological Evaluation of Conformationally Restricted Novel 2-Alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3, 4-dihydro-5-alkylpyrimidin-4(3 H)-ones as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase J. Med. Chem. 2001, 44, 2544-2554 (Pubitemid 32852144)
15. Mugnaini, C.; Alongi, M.; Togninelli, A.; Gevarija, H.; Brizzi, A.; Manetti, F.; Bernardini, C.; Angeli, L.; Tafi, A.; Bellucci, L.; Corelli, F.; Massa, S.; Maga, G.; Samuele, A.; Facchini, M.; Clotet-Codina, I.; Armand-Ugón, M.; Esté, J. A.; Botta, M. Dihydro-alkylthio-benzyl- oxopyrimidines as Inhibitors of Reverse Transcriptase: Synthesis and Rationalization of the Biological Data on Both Wild-Type Enzyme and Relevant Clinical Mutants J. Med. Chem. 2007, 50, 6580-6505 and references therein cited.
16. Nawrozkij, M. B.; Rotili, D.; Tarantino, D.; Botta, G.; Eremiychuk, A. S.; Musmuca, I.; Ragno, R.; Samuele, A.; Zanoli, S.; Armand-Ugón, M.; Clotet-Codina, I.; Novakov, I. A.; Orlinson, B. S.; Maga, G.; Esté, J. A.; Artico, M.; Mai, A. 5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl) pyrimidin-4(3 H)-ones, a Series of Anti-HIV-1 Agents of the Dihydro-alkoxy- benzyl-oxopyrimidine Family with Peculiar Structure-Activity Relationship Profile J. Med. Chem. 2008, 51, 4641-4652
17. Ragno, R.; Mai, A.; Sbardella, S.; Artico, M.; Massa, S.; Musiu, C.; Mura, M.; Marceddu, T.; Cadeddu, A.; La Colla, P. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6- difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3 H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant J. Med. Chem. 2004, 47, 928-934 (Pubitemid 38176795)
18. Mai, A.; Artico, M.; Ragno, R.; Sbardella, G.; Massa, S.; Musiu, C.; Mura, M.; Marturana, F.; Cadeddu, A.; Maga, G.; La Colla, P. 5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3 H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family Bioorg. Med. Chem. 2005, 13, 2065-2077 (Pubitemid 40261127)
19. Mai, A.; Artico, M.; Rotili, D.; Tarantino, D.; Clotet-Codina, I.; Armand-Ugón, M.; Ragno, R.; Simeoni, S.; Sbardella, G.; Nawrozkij, M. B.; Samuele, A.; Maga, G.; Esté, J. A. Synthesis and Biological Properties of Novel 2-Aminopyrimidin-4(3 H)-ones Highly Potent Against HIV-1 Mutant Strains J. Med. Chem. 2007, 50, 5412-5424 (Pubitemid 350057851)
20. Cancio, R.; Mai, A.; Rotili, D.; Artico, M.; Sbardella, G.; Clotet-Codina, I.; Esté, J. A.; Crespan, E.; Zanoli, S.; Hübscher, U.; Spadari, S.; Maga, G. Slow-, Tight-Binding HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors Highly Active against Drug-Resistant Mutants ChemMedChem 2007, 2, 445-448
21. Samuele, A.; Facchini, M.; Rotili, D.; Mai, A.; Artico, M.; Estè, J. A.; Maga, G. Substrate-induced stable enzyme-inhibitor complex formation allows tight binding of novel 2-aminopyrimidin-4(3 H)-ones to drug resistant HIV-1 reverse transcriptase mutants ChemMedChem 2008, 3, 1412-1418
22. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Béthune, M. P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M.; de Jonge, M. R.; Van Aken, K. J.; Daeyaert, F. F.; Das, K.; Arnold, E.; Janssen, P. A. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239 (Pubitemid 32781673)
23. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; De Jonge, M. R.; Koymans, L. M.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; De Bethune, M. P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants J. Med. Chem. 2004, 47, 2550-2560 (Pubitemid 38580092)
24. Janssen, P. A.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Bethune, M. P.; Pauwels, R.; Das, K.; Clark, A. D., Jr.; Frenkel, Y. V.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1 E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-benzonitrile (R278474, rilpivirine) J. Med. Chem. 2005, 48, 1901-1909 (Pubitemid 40396320)
25. Guillemont, J.; Pasquier, E.; Palandjian, P.; Vernier, D.; Gaurrand, S.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M.; Daeyaert, F. F.; Vinkers, M. H.; Arnold, E.; Das, K.; Pauwels, R.; Andries, K.; de Béthune, M. P.; Bettens, E.; Hertogs, K.; Wigerinck, P.; Timmerman, P.; Janssen, P. A. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1 J. Med. Chem. 2005, 48, 2072-2079 (Pubitemid 40396334)
26. Tavares, F. X.; Boucheron, J. A.; Dickerson, S. H.; Griffin, R. J.; Preugschat, F.; Thomson, S. A.; Wang, T. Y.; Zhou, H. Q. N -Phenyl-4-pyrazolo[1, 5- b ]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy J. Med. Chem. 2004, 47, 4716-4730 (Pubitemid 39195562)
27. Gonzalez-Ortega, E.; Mena, M. P.; Permanyer, M.; Ballana, E.; Clotet, B.; Este, J. A. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation Antimicrob. Agents Chemother. 2010, 54, 4487-4492
28. Moncunill, G.; Armand-Ugon, M.; Clotet, I.; Pauls, E.; Ballana, E.; Llano, A.; Romagnoli, B.; Vrijbloed, J. W.; Gombert, F. O.; Clotet, B.; De Marco, S.; Esté, J. A. Anti-HIV Activity and Resistance Profile of the CXCR4 Antagonist POL3026 Mol. Pharmacol. 2008, 73, 1264-1273 (Pubitemid 351439208)
29. Moncunill, G.; Armand-Ugon, M.; Pauls, E.; Clotet, B.; Esté, J. A. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro AIDS 2008, 22, 23-31 (Pubitemid 350294874)
30. Maga, G.; Amacker, M.; Ruel, N.; Hubscher, U.; Spadari, S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions J. Mol. Biol. 1997, 274, 738-747 (Pubitemid 28021342)